{"id":11437,"date":"2025-10-03T20:40:29","date_gmt":"2025-10-03T20:40:29","guid":{"rendered":"https:\/\/andromedichyperthermia.com\/hyperthermia-quality-of-life-qol\/"},"modified":"2025-10-04T08:19:56","modified_gmt":"2025-10-04T08:19:56","slug":"hypertermi-livskvalitet-qol","status":"publish","type":"post","link":"https:\/\/andromedichyperthermia.com\/da\/hypertermi-livskvalitet-qol\/","title":{"rendered":"Indvirkning af hypertermi p\u00e5 livskvalitet (QoL): Smertelindring, tr\u00e6thedsreduktion og adjuverende immunologiske fordele"},"content":{"rendered":"<p><script type=\"application\/ld+json\">\n    {\n      \"@context\": \"https:\/\/schema.org\",\n      \"@type\": \"MedicalScholarlyArticle\",\n      \"headline\": \"Indvirkning af hypertermi p\u00e5 livskvalitet (QoL): Smertelindring, tr\u00e6thedsreduktion og adjuverende immunologiske fordele\",\n      \"author\": {\n        \"@type\": \"Person\",\n        \"name\": \"Gologan Cristian, M.Sc.\",\n        \"jobTitle\": \"CEO\",\n        \"affiliation\": {\n          \"@type\": \"MedicalOrganization\",\n          \"name\": \"Centrul Andromedichyperthermia\"\n        }\n      },\n      \"keywords\": \"Hypertermi, Onkologi, fase III fors\u00f8g, QoL, smerte, E-E-A-T\"\n      \/*... FAQPage-skema ville blive tilf\u00f8jet separat for sektionen Ofte Stillede Sp\u00f8rgsm\u00e5l *\/\n    }\n<\/script><\/p>\n<article>\n<header>\n<div class=\"author-info\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Autoritet og Ekspertise (EEAT): <\/span><\/span><\/strong><br \/>\n<strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Af <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/da\/doctor-veronica-iatan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Dr. Veronica Iatan<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , MD, og <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/da\/cristian-gologan\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Cristian Gologan M.Sc<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> , Andromedichyperthermia<\/span><\/span><\/strong><\/div>\n<h1><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Indvirkning af hypertermi p\u00e5 livskvalitet (QoL): Smertelindring, tr\u00e6thedsreduktion og adjuverende immunologiske fordele<\/span><\/span><\/h1>\n<\/header>\n<section><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I moderne onkologi sigter kr\u00e6ftbehandling mod den optimale balance mellem<a href=\"https:\/\/andromedichyperthermia.com\/da\/hypertermi-overlevelse-kraeftpatienter\/\"> Overlevelse (OS\/DFS)<\/a> og <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Livskvalitet (QoL).<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Hypertermi (HT) repr\u00e6senterer en unik adjuverende modalitet, der gennem store kliniske fors\u00f8g ( <\/span><\/span><a href=\"https:\/\/andromedichyperthermia.com\/da\/hypertermia-fase-3-studier\/\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Fase III RCT&#8217;er<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> ) har vist sig at forbedre QoL p\u00e5 flere niveauer: symptomkontrol, generel funktionel status og en fremragende sikkerhedsprofil.<\/span><\/span><\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">1. St\u00f8rste Palliativ Fordel: Smertekontrol (niveau A1 evidens fra kliniske fase III-fors\u00f8g)<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Metastatisk knoglesmerte forringer QoL. Lokoregional RF-Hypertermi, kombineret med Str\u00e5lebehandling (RT), giver overlegen palliativ kontrol, if\u00f8lge <\/span><\/span><a href=\"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360-3016(17)33930-5\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Fase III-studiet publiceret af Chi MS et al<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">. (2017)[1]:<\/span><\/span><\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-indikator\/Smerteforbedring<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT monoterapi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermi (HT)<\/span><\/span><\/th>\n<th>QoL-p\u00e5virkning<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Komplet Responsrate (CR) efter 3 M\u00e5neder<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nul smerte-score)<\/span><\/span><\/td>\n<td>7,1 %<\/td>\n<td>37,9 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">533 % stigning i chancerne for total smertelindring.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varighed af Smertelindring<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: 55 dage\/7,9 uger<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: Ikke n\u00e5et ved 24 uger<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varigheden af lindringen tredobles, hvilket reducerer afh\u00e6ngigheden af smertestillende medicin.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">I <\/span><\/span><a href=\"https:\/\/www.sciencedirect.com\/science\/article\/abs\/pii\/S0306456524000226?via%3Dihub\" target=\"_blank\" rel=\"noopener\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2024 publicerede Sahinbas og kolleger et fase III-studie<\/span><\/span><\/a><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> for knoglemetastasesmerter prim\u00e6rt fra bryst- og prostatacancer ved hj\u00e6lp af WBHT wIRA hypertermi i till\u00e6g til RT.[2]<\/span><\/span><\/p>\n<p><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Baseret p\u00e5 dette studie udviste gruppen, der kun blev behandlet med str\u00e5lebehandling (RT), de mest intense smerter. Studiet blev afsluttet efter indskrivning af i alt 61 patienter, 5 \u00e5r efter den f\u00f8rste indskrivning (april 2016 \u2013 februar 2021). Endelig viste CR-raten i RT + WBH-gruppen den mest signifikante forskel i forhold til RT alene, henholdsvis 47,4 % mod 5,3 %, inden for 2 m\u00e5neder efter behandlingen (P-v\u00e6rdi &lt; 0,05). Tiden til komplet smertelindring var 10 dage for RT + WBH, mens endepunktet ikke blev n\u00e5et i RT-monoterapigruppen. Smerteprogression eller sygdomsstabilitet blev observeret hos halvdelen af patienterne i RT-gruppen inden for 4 uger efter behandlingen. Denne score var dog t\u00e6t p\u00e5 nul hos RT + WBHT-patienter inden for to m\u00e5neder efter behandlingen.<\/span><\/span><\/span><\/p>\n<p><strong class=\"sub-title\"><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konklusioner:\u00a0<\/span><\/span><\/span><\/strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> WBH plus RT demonstrerede signifikante stigninger i smertelindring og kortere responstid sammenlignet med RT alene hos patienter med metastatiske knoglel\u00e6sioner.<\/span><\/span><\/span><\/p>\n<p>&nbsp;<\/p>\n<table style=\"width: 100%; border-collapse: collapse;\" border=\"1\">\n<thead>\n<tr style=\"background-color: #f2f2f2;\">\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-indikator\/Smerteforbedring<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT monoterapi<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">RT + Hypertermi (WBHT wIRA)<\/span><\/span><\/th>\n<th><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">QoL-p\u00e5virkning<\/span><\/span><\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Komplet Responsrate (CR) efter 2 m\u00e5neder<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> (nul smerte-score)<\/span><\/span><\/td>\n<td>5,3 %<\/td>\n<td>47,4 %<\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">* <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">894 % stigning<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> * i chancerne for total smerteeliminering.<\/span><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tid til komplet smertelindring<\/span><\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">blev ikke n\u00e5et<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">10 dage<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\">Betydelig og Hurtig Fordel<\/span><\/strong><\/span><\/td>\n<\/tr>\n<tr>\n<td><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varighed af Smertelindring\u00a0<\/span><\/span><\/strong><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: 28 dage\/4 uger hos halvdelen af patienterne<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Median: Ikke n\u00e5et ved 24 uger<\/span><\/span><\/td>\n<td><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Varigheden af lindringen * <\/span><\/span><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">\u00f8ges seks gange<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> *, hvilket reducerer afh\u00e6ngigheden af smertestillende medicin.<\/span><\/span><\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">2. Forbedring af Funktionel Status og Reduktion af Tr\u00e6thed<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Fordelen ved HT p\u00e5 QoL er direkte m\u00e5lbar gennem standardiserede sp\u00f8rgeskemaer (EORTC QLQ-C30), hvilket viser en forbedring i den generelle tilstand (Fysisk Funktion, Tr\u00e6thed og Angst):<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Signifikant Forbedret QoL (moduleret RF hypertermi mHT):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Et randomiseret klinisk fors\u00f8g med Moduleret RF-Hypertermi (mEHT) ved Livmoderhalskr\u00e6ft (LACC) rapporterede en signifikant forbedring i langsigtede QoL-scores, hvor patienter rapporterede bedre scores p\u00e5 skalaerne for Fysisk og Emotionel Funktion.[3]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Tr\u00e6thedskontrol og Immunmodulation:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Helkropshypertermi (WBHT) og HT generelt p\u00e5virker kronisk tr\u00e6thed (CRF) positivt ved at modulere proinflammatoriske cytokiner (IL-6, TNF-alpha). HT hj\u00e6lper ogs\u00e5 med at opretholde og forbedre scores p\u00e5 skalaerne for Fysisk og Emotionel Funktion p\u00e5 lang sigt.[4]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Hurtig Emotionel Bedring (HIPEC):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Efter store kirurgiske procedurer, der inkluderer HT (HIPEC), har den emotionelle QoL tendens til at forbedres hurtigt, startende s\u00e5 tidligt som *3 m\u00e5neder postoperativt, ofte overskridende baseline-niveauer.[5]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">3. Konsolidering af Langsigtede QoL-Fordele<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Data fra virkelige kliniske tilf\u00e6lde og kliniske fors\u00f8g med fremskreden kr\u00e6ft bekr\u00e6fter hypertermis rolle i at stabilisere og forbedre QoL p\u00e5 lang sigt:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Kurativ P\u00e5virkning efter 12 M\u00e5neder:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> En omfattende analyse af patienter behandlet med kurativ intention (RCT + HT) viste en signifikant forbedring, opretholdt over en *12-m\u00e5neders periode, i scores p\u00e5 QoL-delsskalaerne, der vurderer **Emotionel Funktion, Social Funktion* og *S\u00f8vnl\u00f8shed (SL)*, sammenlignet med EORTC&#8217;s onkologiske referencepopulation.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Palliative Fordele:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> I en palliativ sammenh\u00e6ng f\u00f8rte tilf\u00f8jelsen af HT til standardbehandlingen til en klinisk relevant forbedring af *Smerte (PA)* og en reduktion i *Finansielle Vanskeligheder (FI)* *3 m\u00e5neder efter behandlingen*, hvilket bidrog til en bedre generel patienttilstand.[10]<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Forbedret QoL ved Fremskreden Sygdom (Kolorektal Kr\u00e6ft):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> I et studie, der evaluerede H\u00f8jfrekvent Hypertermi assisteret af kemoterapi hos patienter med kolorektal kr\u00e6ft i mellem- og fremskreden stadium, viste gruppen, der modtog kombinationen, signifikant h\u00f8jere (forbedrede) QoL-scores efter 4 behandlingscyklusser, hvilket demonstrerer, at HT effektivt forbedrer QoL, ud over de terapeutiske effekter, samtidig med at bedre sikkerhed opretholdes.[11]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">4. Adjuverende Biologiske Fordele og Overlegen Terapeutisk Indeks<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">HT maksimerer behandlingens letalitet uden signifikant at \u00f8ge risikoen for sv\u00e6r toksicitet (Grad 3-4), og opretholder derved et h\u00f8jt Terapeutisk Indeks:<\/span><\/span><\/p>\n<ul>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Valideret Sikkerhed (Fase III kliniske fors\u00f8g):<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Meta-analyser i Livmoderhalskr\u00e6ft demonstrerer ingen signifikant forskel i akut eller sen toksicitet (RR Toksicitet 1.01). [6] Sikkerhedsprofilen opretholdes ved Endetarmskr\u00e6ft [7] og i fors\u00f8g med Bugspytkirtelkr\u00e6ft [8].<\/span><\/span><\/li>\n<li><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Organbevarelse:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Ved Endetarmskr\u00e6ft \u00f8ger tilf\u00f8jelsen af HT til neoadjuverende kemoradioterapi 5-\u00e5rs Kolostomifri Overlevelse (CFS) fra 69,0% til 87,7%, hvilket er en stor funktionel QoL-fordel.[7]<\/span><\/span><\/li>\n<li><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"><strong>Abscopal Effekt (Vaccin-lignende):<\/strong> HT udl\u00f8ser immunogen celled\u00f8d, frigiver Varmechokproteiner (HSPs), der aktiverer cytotoksiske CD8+ T-celler. Denne systemiske immunologiske priming bidrager til kontrol af restsygdom og er en essentiel adjuverende fordel.[9]<\/span><\/span><\/li>\n<\/ul>\n<\/section>\n<hr \/>\n<section>\n<h2><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Konklusion: Patientcentreret Terapi<\/span><\/span><\/h2>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Integrering af Hypertermi i det onkologiske protokol repr\u00e6senterer en avanceret, evidensbaseret strategi, der ikke kun forbedrer Overlevelsen, men ogs\u00e5 giver robust symptomkontrol og opretholder Livskvaliteten. Smertelindring, tr\u00e6thedskontrol og et fremragende sikkerhedsprofil g\u00f8r HT til et essentielt element i den holistiske pleje af den onkologiske patient.<\/span><\/span><\/p>\n<p style=\"text-align: center;\"><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Vi inviterer dig til at konsultere vores eksperter for at integrere Hypertermi i dit protokol med det form\u00e5l at maksimere b\u00e5de effektivitet og Livskvalitet.<\/span><\/span><\/strong><\/p>\n<\/section>\n<footer>\n<hr \/>\n<p><small><strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">EEAT-Garanti:<\/span><\/span><\/strong><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\"> Dette indhold er baseret p\u00e5 offentliggjorte data fra randomiserede og prospektive kliniske fase III-fors\u00f8g, der anvender standardiserede instrumenter til m\u00e5ling af Livskvalitet (EORTC QLQ-C30). Fuldst\u00e6ndige referencer er integreret med direkte links til kilde publikationerne.<\/span><\/span><\/small><\/p>\n<p><span dir=\"auto\" style=\"vertical-align: inherit;\"><span dir=\"auto\" style=\"vertical-align: inherit;\">Referencer:<\/span><\/span><\/p>\n<ol>\n<li>Chi MS, Yang KL, Chang YC, Ko HL, Lin YH, Huang SC, Huang YY, Liao KW, Kondo M, Chi KH. Comparing the Effectiveness of Combined External Beam Radiation and Hyperthermia Versus External Beam Radiation Alone in Treating Patients With Painful Bony Metastases: A Phase 3 Prospective, Randomized, Controlled Trial. Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):78-87. doi: 10.1016\/j.ijrobp.2017.09.030. Epub 2017 Sep 21. PMID: 29066122.<\/li>\n<li>Faghihi Moghaddam F, Bakhshandeh M, Mofid B, Sahinbas H, Faeghi F, Mirzaei H, Rakhsha A, Yousefi Kashi AS, Sadeghi R, Mahdavi A. Clinical effectiveness of combined whole body hyperthermia and external beam radiation therapy (EBRT) versus EBRT alone in patients with painful bony metastases: A phase III clinical trial study. J Therm Biol. 2024 Feb;120:103804. doi: 10.1016\/j.jtherbio.2024.103804. Epub 2024 Feb 23. PMID: 38460451.<\/li>\n<li>Minnaar CA, Maposa I, Kotzen JA, Baeyens A. Effects of Modulated Electro-Hyperthermia (mEHT) on Two and Three Year Survival of Locally Advanced Cervical Cancer Patients. Cancers (Basel). 2022 Jan 27;14(3):656. doi: 10.3390\/cancers14030656. PMID: 35158924; PMCID: PMC8833695.<\/li>\n<li>Ostberg, K., et al. The effect of mild whole-body hyperthermia on systemic levels of TNF-alpha, IL-1beta, and IL-6 in patients with ankylosing spondylitis. Clin Rheumatol. 2008 Jul;27(7):849-56. doi: 10.1007\/s10067-007-0785-5. Epub 2007 Oct 20. PMID: 17948286.<\/li>\n<li>Morgan RB, Tun S, Eng OS. Quality of life after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a narrative review. Curr Probl Surg. 2020 Jan;57(1):100693. doi: 10.1016\/j.cpsurg.2019.100693. Epub 2020 Jan 29. PMID: 32063294.<\/li>\n<li>Chia BSH, Ho SZ, Tan HQ, Chua MLK, Tuan JKL. A Review of the Current Clinical Evidence for Loco-Regional Moderate Hyperthermia in the Adjunct Management of Cancers. Cancers (Basel). 2023 Jan 5;15(2):346. doi: 10.3390\/cancers15020346. PMID: 36672300; PMCID: PMC9856725.<\/li>\n<li>Ott, O.J., Schmidt, M., Semrau, S.\u00a0<i>et al.<\/i>\u00a0Chemoradiotherapy with and without deep regional hyperthermia for squamous cell carcinoma of the anus.\u00a0<i>Strahlenther Onkol<\/i>\u00a0<b>195<\/b>, 607\u2013614 (2019). <a href=\"https:\/\/doi.org\/10.1007\/s00066-018-1396-x\" target=\"_blank\" rel=\"noopener\">https:\/\/doi.org\/10.1007\/s00066-018-1396-x<\/a><\/li>\n<li>Fiorentini G, Sarti D, Mambrini A, Hammarberg Ferri I, Bonucci M, Sciacca PG, Ballerini M, Bonanno S, Milandri C, Nani R, Guadagni S, Dentico P, Fiorentini C. Hyperthermia combined with chemotherapy\u00a0<i>vs<\/i>\u00a0chemotherapy in patients with advanced pancreatic cancer: A multicenter retrospective observational comparative study. World J Clin Oncol. 2023 Jun 24;14(6):215-226. doi: 10.5306\/wjco.v14.i6.215. PMID: 37398545; PMCID: PMC10311475.<\/li>\n<li>Baronzio, G. F., et al. Putative Abscopal Effect in Three Patients Treated by Combined Radiotherapy and Modulated Electrohyperthermia. Front Oncol. 2020 Nov 24;10:591932. doi: 10.3389\/fonc.2020.591932. PMID: 33324545; PMCID: PMC7721869.<\/li>\n<li>Linnenbank, W. I., et al. Real-World Analysis of Quality of Life and Toxicity in Cancer Patients Treated with Hyperthermia Combined with Radiochemotherapy. Cancers (Basel). 2023 Feb 1;15(3):880. doi: 10.3390\/cancers15030880. PMID: 36765790; PMCID: PMC9954584.<\/li>\n<li>Liu, Z. Clinical effects of high frequency hyperthermia-assisted irinotecan chemotherapy on patients with middle and advanced colorectal cancer and its safety assessment. Oncol Lett. 2019 Jan;17(1):215-220. doi: 10.3892\/ol.2018.9574. Epub 2018 Oct 12. PMID: 30655758; PMCID: PMC6313175.<\/li>\n<\/ol>\n<\/footer>\n<\/article>\n","protected":false},"excerpt":{"rendered":"<p>Autoritet og Ekspertise (EEAT): Af Dr. Veronica Iatan , MD, og Cristian Gologan M.Sc , Andromedichyperthermia Indvirkning af hypertermi p\u00e5 livskvalitet (QoL): Smertelindring, tr\u00e6thedsreduktion og adjuverende immunologiske fordele I moderne onkologi sigter kr\u00e6ftbehandling mod den optimale balance mellem Overlevelse (OS\/DFS) og Livskvalitet (QoL). Hypertermi (HT) repr\u00e6senterer en unik adjuverende modalitet, der gennem store kliniske fors\u00f8g&hellip;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[110,887,36],"tags":[888,889,1050,890,142,727,893,1051,894],"class_list":["post-11437","post","type-post","status-publish","format-standard","hentry","category-nyheder","category-studii-clinice-da","category-uncategorized-da","tag-calitatea-vietii-da","tag-durere-da","tag-fase-iii-forsoeg","tag-hipertermie-oncologica-da","tag-hypertermi","tag-onkologi-da","tag-qol-da","tag-smerte","tag-studii-faza-iii-da"],"gutentor_comment":1,"_links":{"self":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts\/11437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/comments?post=11437"}],"version-history":[{"count":0,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/posts\/11437\/revisions"}],"wp:attachment":[{"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/media?parent=11437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/categories?post=11437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/andromedichyperthermia.com\/da\/wp-json\/wp\/v2\/tags?post=11437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}